US5045537A - Hydrophilic renin inhibitors, their preparation and use - Google Patents
Hydrophilic renin inhibitors, their preparation and use Download PDFInfo
- Publication number
- US5045537A US5045537A US07/244,220 US24422088A US5045537A US 5045537 A US5045537 A US 5045537A US 24422088 A US24422088 A US 24422088A US 5045537 A US5045537 A US 5045537A
- Authority
- US
- United States
- Prior art keywords
- group
- formula
- hydrogen
- signifies
- chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0227—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the (partial) peptide sequence -Phe-His-NH-(X)2-C(=0)-, e.g. Renin-inhibitors with n = 2 - 6; for n > 6 see C07K5/06 - C07K5/10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to novel hydrophilic renin inhibitors, their preparation and use as well as pharmaceutical compositions containing them.
- hydrophilic renin inhibitors of formula ##STR2## wherein W is --O--, --NR 2 -- or --CH 2 , whereby R 2 signifies hydrogen or a straight-chain or branched (C 1-5 )alkyl radical,
- R 1 is hydrogen, a straight-chain or branched (C 1-20 )alkyl radical or a sugar radical which is bonded as a glycoside; an optionally substituted, saturated or unsaturated, straight-chain or branched (C 2-30 )alkylcarbonyl group, (C 3-6 )polyhydroxyalkylcarbonyl-, a phosphoroyl-, a bis-(dimethylamino)-phosphoroyl-, a sulpho-, an aroyl-, a heteroaroyl-, an arylalkyl-, an arylalkylcarbonyl-, a heteroarylalkylcarbonyl-or a biotinyl group, or
- R 1 signifies a group of formula ##STR3## wherein R 15 is hydrogen or a side chain of a D- or L-amino acid, and
- R 16 and R 17 are the same or different and respectively signify hydrogen, (C 1-5 )alkyl, (C 2-5 )hydroxyalkyl or (C 2-5 )aminoalkyl, or
- R 1 signifies a group of formula ##STR4## wherein R 16 and R 17 are defined as above,
- p denotes a whole number from 0 to 5 and
- n is a whole number from 1 to 20,
- n is a whole number from 0 to 5
- o 2 or 3
- A, B and C are the same or different and signify a bond or a group of formula ##STR7## wherein R 2 is defined as above, and
- R 3 signifies a hydrophilic or lipophilic amino acid side chain
- R 2 and R 3 together form a --(CH 2 ) o -- chain, wherein o is defined as above,
- D signifies either a group of formula ##STR8## wherein R 4 has the same significance as R 3 ,
- R 5 is a hydroxyl or an amino group
- R 6 is hydrogen, or
- R 5 and R 6 together form an oxo group
- R 7 and R 8 independently of one another, signify fluorine or hydrogen
- R 9 and R 10 are the same or different and respectively signify hydrogen, a straight-chain or branched (C 1-5 )-alkyl radical, or they respectively signify a group of formula ##STR9## wherein R 11 signifies a straight-chain or branched (C 1-5 )-alkyl radical or a straight-chain or branched (C 1-5 )-hydroxyalkyl radical,
- R 12 is a hydroxyl radical, a straight-chain or branched (C 1-5 )-alkoxy group, an amino group or a (C 1-5 )-alkylamino group, an aminomethylpyridyl group, a benzyl group or a group of formula ##STR10## wherein R 1 and m are defined as above, or R 1 denote a protected or unprotected amino acid,
- X signifies a bond, or denotes ##STR11## wherein R 13 and R 14 , independently of one another, denote hydrogen or fluorine, or respectively possess the definition given above for R 3 , or
- D signifies a group of formula ##STR12## wherein R 4 , R 5 , R 9 , R 10 and X possess the definitions given above, and
- Z is ##STR13## or D signifies a group of formula ##STR14## wherein R 4 , R 11 and R 12 possess the definitions given above, and their salts.
- Asymmetrically substituted carbon atoms may have R- or S-configuration.
- the configurations given in the following formula I y are preferred.
- the hydrophilic renin inhibitors are referred to hereinafter as compounds according to the invention.
- the compounds according to the invention are notable for advantageous hydrophilic properties, and are even partly water-soluble.
- the compounds according to the invention have high affinity for human renin even in the presence of plasma protein (i.e. they are only weakly bonded to plasma protein such as albumin etc.). These properties allow the compounds according to the invention to be advantageously differentiated from previously known renin inhibitors.
- a straight-chain or branched alkyl is especially an alkyl with 1 to 5 carbon atoms, especially ethyl, propyl or isobutyl, the sugar radical which is bonded as a glycoside is for example glucopyranosyl which may be optionally O-acylated, e.g.
- an optionally substituted saturated or unsaturated (C 2-30 )alkylcarbonyl group is in particular a corresponding (C 4-20 )alkylcarbonyl group, for example a palmitoyl, oleyl, linoyl, stearoyl or pivaloyl radical, whereby the alkylcarbonyl group may be substituted by a cyclopentaphenanthrene radical and may denote a cholyl radical
- a (C 3-6 )polyhydroxyalkylcarbonyl radical is for example a glycerinoyl or a gluconoyl radical which may be optionally substituted, and may be for example a penta-O-acetylgluconoyl or dibutyroylglycerinoyl radical
- an aroyl radical is for example the benzoyl radical
- a heteroaroyl is for example the 2-, 3- or 4-
- a side chain of a D- or L-amino acid is in particular methyl, isopropyl, isobutyl, benzyl, hydroxy(C 1-5 )alkyl, 4-aminobutyl or 2-carboxyethyl.
- the hydrophilic or lipophilic amino acid side chain in the definition of R 3 may be for example a isopropyl, n-butyl, isobutyl, 2-butenyl, benzyl optionally substituted in paraposition by a methoxy group, a 4-imidazolylmethyl, 2-methylthioethyl, methylthiomethyl, trimethylsilylmethyl, cyclohexylmethyl, a 2-thienylmethyl-, an 1-adamantylmethyl or a pyridylmethyl radical or a halogen like e.g. chlorine.
- Hydroxyalkyl with 1 to 5 carbon atoms is preferably hydroxyethyl or hydroxypropyl, and an alkoxy group with 1 to 5 carbon atoms preferably signifies methoxy or ethoxy.
- Preferred compounds of formula I possess formula I y ##STR15## wherein R 1 y signifies hydrogen, methyl or glucopyranosyl,
- m y signifies a whole number from 2 to 7 and
- n y signifies 0 or 1
- a y signifies a bond or proline
- B y signifies a group of formula ##STR16## whereby R 3 y signifies cyclohexylmethyl, benzyl, trimethylsilylmethyl, p-methoxybenzyl, 1-adamantylmethyl or isobutyl.
- C y signifies a group of formula ##STR17## whereby R 3 y' is n-butyl, isobutyl, 2-butenyl, benzyl, 4-imidazolylmethyl or pyridylmethyl.
- D y is a group of formula ##STR18## wherein R 4 y is isobutyl, benzyl or cyclohexylmethyl, and either
- R 5 y signifies a hydroxyl radical
- R 6 y signifies hydrogen
- R 7 y and R 8 y respectively denote hydrogen, or
- R 7 y and R 8 y respectively denote fluorine
- X y signifies a bond or a group of formula ##STR19## wherein either R 13 y and R 14 y respectively signify fluorine, or
- R 14 y has the definition n-butyl, isobutyl, 2-butenyl, methylthiomethyl, benzyl, isopropyl or chlorine and
- R 13 y denotes hydrogen
- R 9 y signifies hydrogen
- R 10 y signifies hydrogen, methyl, i-propyl, i-butyl, 2-butyl or a group of formula ##STR20## wherein R 11 y denotes i-butyl or 2-butyl and
- R 12 y denotes aminomethylpyridyl.
- stage b) is effected such that alcohols of the compounds of formula I are oxidised with a chromium trioxide dipyridine complex (Collin's reagent) in a solvent such as methylene chloride or dimethylformamide, to form the corresponding ketone.
- a chromium trioxide dipyridine complex Cold's reagent
- the starting compounds used in the above processes are either known or may be produced by known processes, for example as described in the following examples.
- the compounds of formula I produced according to the invention may be isolated and purified by known processes. Racemic and/or diastereoisomeric mixtures can be separated in known manner.
- the compounds of formula I may optionally also form salts, for example metal salts such as sodium salts or acid addition salts such as hydrochlorides.
- the starting product used in this example may be produced as follows:
- the compounds according to the invention exhibit pharmacological activity and are, therefore, useful as pharmaceuticals.
- renin activity e.g. on human tetradecapeptide substrate at a concentration of 10 -5 M to 10 -11 M they inhibit the enzyme activity of pure human renin by 50% according to the method of F. Cumin et al. (Bioch. Biophys. Acta 913, 10 to 19 (1987)) or in a renin binding assay.
- the compounds according to the invention are therefore useful for the prophylaxis and treatment of conditions which are characterised by enzymatic malfunction and for which an inhibition of enzymatic activity is indicated.
- renin inhibitors they are suitable e.g. for use in the prophylaxis and treatment of hypertension and cardiac insufficiency ("congestive heart failure").
- the compounds which are preferred for the prophylaxis and treatment of hypertension and cardiac insufficiency are the title compounds of examples 2, 3, 8 to 11, 13, 18, 19, 21 and 46, especially of examples 8 to 11, 13, 21 and 46, particularly of examples 13, 21 and 46, most preferred the compound of example 46.
- the compounds according to the invention exhibit also an antiretroviral activity and are therefore useful for the treatment of diseases caused by retroviruses including HTLV-I and -III.
- This activity can be demonstrated in the FeLV cat model [Cerny and Essex, CRC press in 1979, pp. 233-256; Cockerell et al., J. Natl. Cancer Inst. 57, 1095-1099 (1976); Cotter et al. J. Am. Vet. med. Assoc. 166, 449-453 (1975); Essex et al. Science 190, 790-792 (1975)]- a disease model for human AIDS.
- the dosage to be administered depends on the compound respectively used, the type of administration and the desired treatment. In general, satisfactory results are obtained if the compounds are administered in a daily dosage of 0.02 mg/kg to ca. 20 mg/kg animal body weight. For larger mammals, for example humans an indicated daily dosage is from about 1 mg to about 500 mg, conveniently administered e.g. orally in doses of 0.25 mg to ca. 500 mg up to 4 times daily e.g. in divided form.
- the compounds according to the invention may be administered in free form, or if acidic or basic groups are present, in pharmacologically acceptable salt form.
- Such salt forms have the same order of activity as the free forms and can be produced in known manner.
- the present invention similarly relates to pharmaceutical preparations containing a compound according to the invention in free form or in pharmaceutically acceptable salt form, optionally together with pharmaceutically adjuvants and/or carrier substances.
- Such pharmaceutical preparations may be formulated for use in enteral, preferably oral administration, e.g. at tablets, or for use in parenteral administration, e.g. as injectable solutions or suspensions.
- An appropriate nasal spray can be prepared in a manner known per se.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Hydrophilic renin inhibitors, especially of formula ##STR1## wherein R1, W, o, m, n, A, B, C and D possess the definitions given in claim 2, processes for their production and their use in the treatment of hypertension, cardiac insufficiency and the treatment of diseases caused by retroviruses.
Description
The present invention relates to novel hydrophilic renin inhibitors, their preparation and use as well as pharmaceutical compositions containing them.
Especially the invention provides hydrophilic renin inhibitors of formula ##STR2## wherein W is --O--, --NR2 -- or --CH2, whereby R2 signifies hydrogen or a straight-chain or branched (C1-5)alkyl radical,
R1 is hydrogen, a straight-chain or branched (C1-20)alkyl radical or a sugar radical which is bonded as a glycoside; an optionally substituted, saturated or unsaturated, straight-chain or branched (C2-30)alkylcarbonyl group, (C3-6)polyhydroxyalkylcarbonyl-, a phosphoroyl-, a bis-(dimethylamino)-phosphoroyl-, a sulpho-, an aroyl-, a heteroaroyl-, an arylalkyl-, an arylalkylcarbonyl-, a heteroarylalkylcarbonyl-or a biotinyl group, or
R1 signifies a group of formula ##STR3## wherein R15 is hydrogen or a side chain of a D- or L-amino acid, and
R16 and R17 are the same or different and respectively signify hydrogen, (C1-5)alkyl, (C2-5)hydroxyalkyl or (C2-5)aminoalkyl, or
R1 signifies a group of formula ##STR4## wherein R16 and R17 are defined as above,
p denotes a whole number from 0 to 5 and
E signifies a bond or the group ##STR5## or R1 signifies a group of formula
F--(CH.sub.2).sub.p --E--
wherein
p and E are defined as above, and
F denotes groups of formulae ##STR6## whereby R2 is defined as above,
m is a whole number from 1 to 20,
n is a whole number from 0 to 5, and
o is 2 or 3,
A, B and C are the same or different and signify a bond or a group of formula ##STR7## wherein R2 is defined as above, and
R3 signifies a hydrophilic or lipophilic amino acid side chain, or
R2 and R3 together form a --(CH2)o -- chain, wherein o is defined as above,
D signifies either a group of formula ##STR8## wherein R4 has the same significance as R3,
R5 is a hydroxyl or an amino group, and
R6 is hydrogen, or
R5 and R6 together form an oxo group,
R7 and R8, independently of one another, signify fluorine or hydrogen,
R9 and R10 are the same or different and respectively signify hydrogen, a straight-chain or branched (C1-5)-alkyl radical, or they respectively signify a group of formula ##STR9## wherein R11 signifies a straight-chain or branched (C1-5)-alkyl radical or a straight-chain or branched (C1-5)-hydroxyalkyl radical,
R12 is a hydroxyl radical, a straight-chain or branched (C1-5)-alkoxy group, an amino group or a (C1-5)-alkylamino group, an aminomethylpyridyl group, a benzyl group or a group of formula ##STR10## wherein R1 and m are defined as above, or R1 denote a protected or unprotected amino acid,
X signifies a bond, or denotes ##STR11## wherein R13 and R14, independently of one another, denote hydrogen or fluorine, or respectively possess the definition given above for R3, or
D signifies a group of formula ##STR12## wherein R4, R5, R9, R10 and X possess the definitions given above, and
Z is ##STR13## or D signifies a group of formula ##STR14## wherein R4, R11 and R12 possess the definitions given above, and their salts.
Asymmetrically substituted carbon atoms may have R- or S-configuration. The configurations given in the following formula Iy are preferred. The hydrophilic renin inhibitors are referred to hereinafter as compounds according to the invention.
In contrast to the conventional renin inhibitors, the compounds according to the invention are notable for advantageous hydrophilic properties, and are even partly water-soluble. The compounds according to the invention have high affinity for human renin even in the presence of plasma protein (i.e. they are only weakly bonded to plasma protein such as albumin etc.). These properties allow the compounds according to the invention to be advantageously differentiated from previously known renin inhibitors.
In R1 of formula I a straight-chain or branched alkyl is especially an alkyl with 1 to 5 carbon atoms, especially ethyl, propyl or isobutyl, the sugar radical which is bonded as a glycoside is for example glucopyranosyl which may be optionally O-acylated, e.g. tetra-O-acetyl-glucopyranosyl, an optionally substituted saturated or unsaturated (C2-30)alkylcarbonyl group is in particular a corresponding (C4-20)alkylcarbonyl group, for example a palmitoyl, oleyl, linoyl, stearoyl or pivaloyl radical, whereby the alkylcarbonyl group may be substituted by a cyclopentaphenanthrene radical and may denote a cholyl radical, a (C3-6)polyhydroxyalkylcarbonyl radical is for example a glycerinoyl or a gluconoyl radical which may be optionally substituted, and may be for example a penta-O-acetylgluconoyl or dibutyroylglycerinoyl radical, an aroyl radical is for example the benzoyl radical, a heteroaroyl is for example the 2-, 3- or 4-pyridoyl radical, especially a 3-pyridoyl radical, an arylalkyl radical is for example the benzyl, phenethyl, naphthylmethyl, p-chlorophenoxypropyl-2 radical, an arylalkylcarbonyl radical is for example a phenylacetyl, bis(1-naphthylmethyl)acetyl or p-chlorophenoxy-1,1-dimethylacetyl radical, a heteroarylalkylcarbonyl group is for example a bis-( 3-pyridylmethyl)acetyl or a bis(4-quinolinylmethyl)acetyl radical. In R15, a side chain of a D- or L-amino acid is in particular methyl, isopropyl, isobutyl, benzyl, hydroxy(C1-5)alkyl, 4-aminobutyl or 2-carboxyethyl.
The hydrophilic or lipophilic amino acid side chain in the definition of R3 may be for example a isopropyl, n-butyl, isobutyl, 2-butenyl, benzyl optionally substituted in paraposition by a methoxy group, a 4-imidazolylmethyl, 2-methylthioethyl, methylthiomethyl, trimethylsilylmethyl, cyclohexylmethyl, a 2-thienylmethyl-, an 1-adamantylmethyl or a pyridylmethyl radical or a halogen like e.g. chlorine.
Hydroxyalkyl with 1 to 5 carbon atoms is preferably hydroxyethyl or hydroxypropyl, and an alkoxy group with 1 to 5 carbon atoms preferably signifies methoxy or ethoxy.
Preferred compounds of formula I possess formula Iy ##STR15## wherein R1 y signifies hydrogen, methyl or glucopyranosyl,
my signifies a whole number from 2 to 7 and
ny signifies 0 or 1,
Ay signifies a bond or proline,
By signifies a group of formula ##STR16## whereby R3 y signifies cyclohexylmethyl, benzyl, trimethylsilylmethyl, p-methoxybenzyl, 1-adamantylmethyl or isobutyl.
Cy signifies a group of formula ##STR17## whereby R3 y' is n-butyl, isobutyl, 2-butenyl, benzyl, 4-imidazolylmethyl or pyridylmethyl.
Dy is a group of formula ##STR18## wherein R4 y is isobutyl, benzyl or cyclohexylmethyl, and either
R5 y signifies a hydroxyl radical and
R6 y signifies hydrogen where
R7 y and R8 y respectively denote hydrogen, or
R5 y and R6 y together form the oxo group where
R7 y and R8 y respectively denote fluorine,
Xy signifies a bond or a group of formula ##STR19## wherein either R13 y and R14 y respectively signify fluorine, or
R14 y has the definition n-butyl, isobutyl, 2-butenyl, methylthiomethyl, benzyl, isopropyl or chlorine and
R13 y denotes hydrogen,
R9 y signifies hydrogen and
R10 y signifies hydrogen, methyl, i-propyl, i-butyl, 2-butyl or a group of formula ##STR20## wherein R11 y denotes i-butyl or 2-butyl and
R12 y denotes aminomethylpyridyl.
The preparation of compounds of formula I is characterised in that
a) a compound of formula II, ##STR21## wherein R1, W, o, m and n possess the definitions given above and Q denotes a hydroxyl or a p-nitrophenyl radical, is reacted with a compound of formula,
H--A--B--C--D III
wherein A, B, C and D possess the definitions given above, or
b) a compound of formula I, wherein R5 is a hydroxyl radical and R6 is hydrogen, is oxidised to a compound of formula I, wherein R5 and R6 together form an oxo group.
The process according to stage a) is preferably effected such that an acid of formula II (Q=OH) is reacted with an amine of formula III using processes which are known in peptide chemistry, e.g. in the presence of N,N'-dicyclohexylcarbodiimide or N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide (whilst adding 1-hydroxybenzotriazole) in a suitable solvent such as methylene chloride, at temperatures between 0° and room temperature. Alternatively, activated acid derivatives (Q=p-nitrophenyl) can also be reacted directly with the amine at temperatures between 20° and 80°.
The process according to stage b) is effected such that alcohols of the compounds of formula I are oxidised with a chromium trioxide dipyridine complex (Collin's reagent) in a solvent such as methylene chloride or dimethylformamide, to form the corresponding ketone.
The starting compounds used in the above processes are either known or may be produced by known processes, for example as described in the following examples.
The compounds of formula I produced according to the invention may be isolated and purified by known processes. Racemic and/or diastereoisomeric mixtures can be separated in known manner.
If the compounds of formula I contain acidic or basic groups, they may optionally also form salts, for example metal salts such as sodium salts or acid addition salts such as hydrochlorides.
In the following examples, all temperatures are given in degrees celsius and are uncorrected.
The compounds given in abbreviated form in the examples are written out fully in claim 4 in order of the examples beginning with Example 2.
In the following examples, the following abbreviations are used:
______________________________________ H-Bly-OH (2S)-2-amino-hex-(4)-ene-carboxylic acid 3EG-OH 3,6,9,12-tetraoxatridecanoic acid 7EG-OH 3,6,9,12,15,18,21,24-octaoxa-pentacosanic acid PEG-OH oligomeric mixture of polyoxacarboxylic acids H-SO.sub.2 Chatin-OH (2R,3S)-3-amino-4-cyclohexyl-2-hydroxy- butane-sulphonic acid H-Cha(OH)Bly-OH (2R,4S,5S)-5-amino-2-(E-2-butenyl)-6- cyclo-hexyl-4-hydroxy-caproic acid H-Chatin-OH (3S,4S)-4-amino-5-cyclohexyl-3-hydroxy- valeric acid H-F.sub.2 Chatin-OH (3R,4S)-4-amino-5-cyclohexyl-2,2-difluoro- 3-hydroxy-valeric acid H-F.sub.2 Chaton-OH (4S)-4-amino-5-cyclohexyl-2,2-difluoro-3- oxo-valeric acid H-Tmsal-OH (2R)-2-amino-3-trimethylsilyl-propionic acid H-4eg-OH 2,5,8,11,14-pentaoxamyristic acid Glyc-OH β-D-glucopyranoside AcGlyc-OH 2,3,4,6-tetraacetyl-β-D-glucopyranoside Stear-OH stearic acid Linol-OH linoleic acid Chol-OH cholic acid Dinac-OH (bis-1-naphthylmethyl)-acetic acid H-Cha-OH (2S)-2-amino-3-cyclohexyl-propionic acid H-Ada-OH (2S)-2-amino-3-(1-adamantyl)-propionic acid H-Thala-OH (2S)-2-amino-3-(2-thienyl)propionic acid Niacin nicotinoyl Tmpac 3,4,5-trimethoxyphenylacetyl Clof (p-chlorphenoxy)dimethylacetyl H-2eg-OH 2,5,8-trioxaoctanic acid H-3eg-OH 2,5,8,11-tetraoxaundecanic acid H-Cha(OH)Bualy-OH (2R,4S,5S)-5-amino-2-N-butyl-amino-6- cyclo-hexyl-4-hydroxy-capronic acid α-Pic 2-aminomethyl-pyridine ______________________________________
35 mg of H-Phe-His-SO2 Chatin-NH2 are reacted in 0.5 ml of tetrahydrofuran with 10 mg of hydroxybenzotriazole, 60 mg of PEG-OH and 13 mg of N,N'-dicyclohexylcarbodiimide. After 15 hours, the precipitated dicyclohexylurea is filtered off, and the crude product is chromatographed on silica gel with methanol/methylene chloride (5:95).
55 mg of H-Phe-His-Cha(OH)Bly-NHBu are reacted analogously to example 1 with 20 mg of hydroxybenzotriazole, 33 mg of 7EG-OH and 18 mg of N,N'-dicyclohexylcarbodiimide in 0.5 ml of dimethylformamide. The crude product is precipitated from methanol/methylene chloride/ether. [α]D 20 =-20.9° (c=0.2 in CH2 Cl2).
100 mg of H-Phe-Nle-Cha-Leu-α-picoline are reacted analogously to example 1 with 20 mg of hydroxybenzotriazole, 59 mg of 7EG-OH and 31 mg of N,N'-dicyclohexylcarbodiimide. The product is crystallised from methylene chloride/ether/hexane. [α]D 20 =-4.8° (c=0.1 in CH2 Cl2).
100 mg of H-(Phe)-Nle-Chatin-Leu-α-picoline are reacted exactly as in example 1 with 20 mg of hydroxybenzotriazole, 33 mg of 3EG-OH and 31 mg of N,N'-dicyclohexylcarbodiimide. [α]D 20 =-5.2° (c=0.1 in CH2 Cl2).
78 mg of H-Pro-Phe-Nle-Chatin-Leu-α-picoline are reacted analogously to example 1 with 20 mg of hydroxybenzotriazole, 40 mg of 7EG-OH and 20 mg of N,N'-dicyclohexylcarbodiimide. The crude product is chromatographed on silica gel with methanol/methylene chloride (5:95). [α]D 20 =-30.3° (c=0.6 in CH2 Cl2).
59 mg of H-Tmsal-Bly-F2 Chatin-NHiBu are reacted analogously to example 1 in 1 ml of methylene chloride/tetrahydrofuran (9:1) with 29 mg of hydroxybenzotriazole, 43 mg of 7EG-OH and 23 mg of N,N'-dicyclohexylcarbodiimide. The product is then chromatographed with methanol/methylene chloride (1 to 10%). [α]D 20 =-18.8° (c=1.8 in CH2 Cl2).
23 mg of the title compound of example 6 are dissolved in 1 ml of dry methylene chloride, and mixed with 130 mg of Collin's reagent. After 30 minutes, the product is filtered over silica gel, washed with ethyl acetate and concentrated by evaporation. [α]D 20 =-20.6° (c=0.3 in CH2 Cl2).
223 mg of H-Phe-His-Cha(OH)Bly-NHBu in 2 ml of dimethylformamide are reacted analogously to example 1 with 60 g of hydroxybenzotriazole, 85 mg of 3EG-OH and 80 mg of N,N'-dicyclohexylcarbodiimide. The crude product is purified on silica gel with methanol/methylene chloride (5:95). [α]D 20 =-23.2° (c=0.15 in CH2 Cl2).
200 mg of H-Phe-Nle-Cha(OH)Bly-NHBu are reacted analogously to example 1 in 2 ml of dimethylformamide with 50 mg of hydroxybenzotriazole, 140 mg of 7EG-OH and 70 mg of N,N'-dicyclohexylcarbodiimide. The crude product is crystallised from methylene chloride/ether/hexane. [α]D 20 =-31.3° (c=0.1 in CH2 Cl2).
115 mg of AcGlyc-4eg-p-nitrophenol are refluxed for 24 hours with 100 mg of H-Phe-Nle-Cha(OH)GlyNH-Bu in 5 ml of tetrahydrofuran, whilst adding 20 mg of dimethylaminopyridine and 20 mg of N-methylmorpholine. The crude product is dissolved in ethyl acetate, extracted with aqueous Na-bicarbonate solution, dried over magnesium sulphate, concentrated by evaporation and recrystallised from methylene chloride/ether. The title compound has a [α]D 20 =-80° (c=0.05 in CH2 Cl2).
100 mg of the tetraacetate of example 10 are dissolved in 1 ml of methanol, and mixed with a few drops of a 5% solution of sodium methylate in methanol. After 1 hour, the product is diluted with ethyl acetate, washed with aqueous Na bicarbonate solution, dried over magnesium sulphate, concentrated by evaporation and crystallised from methanol/methylene chloride/ether. The title compound has a [α]D 20 =-33.6° (c=0.1 in MeOH/CH2 Cl2 [1:1]).
340 mg of stear-4eg-p-nitrophenol are reacted analogously to example 10 with 290 mg of H-Phe-Nle-Cha(OH)BlyNH-Bu, 60 mg of N-methylmorpholine and 30 mg of dimethylaminopyridine. The crude product is chromatographed with 2% methanol in methylene chloride and crystallised from methylene chloride/ether. The title compound has a [α]D 20 =-18.0° (c=0.15 in CH2 Cl2).
32 mg of the stearate of example 12 are cleaved with sodium methylate in methanol analogously to example 11. The title compound has a [α]D 20 =-24.3° (c=0.1 in CH2 Cl2).
450 mg of linol-4eg-p-nitrophenol are reacted analogously to example 10 with 400 mg of H-Phe-Nle-Cha(OH)BlyNH-Bu, 90 mg of N-methylmorpholine and 30 mg of dimethylamino-pyridine. After chromatography on silica gel with 3% methanol in methylene chloride, there follows recrystallisation from methylene chloride/ether. The title compound has a [α]D 20 =-17.1° (c=0.15 in CH2 Cl2).
525 mg of dinac-4eg-p-nitrophenol are reacted analogously to example 10 with 400 mg of H-Phe-Nle-Cha(OH)BlyNH-Bu, 80 mg of N-methylmorpholine and 30 mg of dimethylaminopyridine. The product is chromatographed with 6% methanol in methylene chloride and is crystallised from methylene chloride/ether. The title compound has a [α]D 20 =-16.8° (c=0.15 in CH2 Cl2).
600 mg of chol-4eg-p-nitrophenol are reacted exactly as in example 10 with 300 mg of H-Phe-Nle-Cha(OH)BlyNH-Bu, 70 mg of N-methylmorpholine and 30 mg of dimethylaminopyridine. The crude product is recrystallised from methanol/methylene chloride/ether.
540 mg of BOC-Gly-4eg-p-nitrophenol are reacted analogously to example 10 with 500 mg of H-Phe-Nle-Cha(OH)BlyNH-Bu, 110 mg of N-methylmorpholine and 30 mg of dimethylaminopyridine. The crude product is recrystallised from methylene chloride/ether. The title compound has a [α]D 20 =-23.6° (c=0.1 in CH2 Cl2).
400 mg of the title compound of example 17 are dissolved in 4 ml of methylene chloride and mixed at 0°-5° with 4 ml of trifluoroacetic acid. After 1/2 hour, the solution is partitioned between aqueous 2N soda solution and methylene chloride, the organic phase is dried over potassium carbonate and concentrated by evaporation. The residue is dissolved in methanol, mixed with 0.1 ml of conc. hydrochloric acid, concentrated by evaporation and crystallised from methanol/methylene chloride/ether. The title compound has a [α]D 20 =-30.0° (c=0.1 in MeOH/CH2 /Cl2 [1:1]).
500 mg of H-Cha-His-Cha(OH)BlyNH-Bu are reacted analogously to example 1 with 200 mg of 3EG-OH, 120 mg of 1-hydroxybenzotriazole and 0.13 ml of dicyclohexylcarbodiimide in dimethylformamide. The crude product is chromatographed with 10% methanol/methylene chloride, and is crystallised from methanol/methylene chloride/ether. The title compound has a [α]D 20 =-34.0° (c=0.1 in MeOH/CH2 Cl2 [1:1]).
The title compound is obtained analogously to example 4 from 284 mg of (2S,3S)-3-(H-Phe-Nle)amido-1-(isopropylcarbamoyl)-amino-4-cyclohexyl-2-butanol.hydrochloride, (obtainable by means of BOC cleavage according to known processes from (2S,3S)-3-(N-BOC-Phe-Nle-)amido-1-(isopropylcarbamoyl)amino-4-cyclohexyl-2-butanol), 111 mg of 3EG-OH, 156 mg of 1-hydroxybenzotriazole, 99 mg of N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide.hydrochloride and 0.07 ml of triethylamine. It has a m.p. of 125°-128°, [α]D 20 =-12.4° (c=1 in methanol).
The starting compound used in example 20, (2S,3S)-3-(N-BOC-Phe-Nle)amido-1-(isopropylcarbamoyl)amino-4-cyclohexyl-2-butanol, is obtained as follows:
A solution of 273 mg of (2S,3S)-1-amino-3-(N-BOC-phenylalaninylnorleucyl)-amido-4-cyclohexyl-2-butanol in 10 ml of anhydrous tetrahydrofuran is mixed at 0° with 0.055 ml of isopropylisocyanate, stirred for 1 hour at room temperature and concentrated by evaporation under a high vacuum. Crystallisation of the residue from methylene chloride/methanol/hexane yields the title compound. M.p. 167°-168° C. (decomp.), [α]D 20 =-16.2° (c=1 in methanol).
The starting product used in this example may be produced as follows:
a) (2S,3S)-3-BOC-amino-1-Cbz.-amino-4-cyclohexyl-2-butanol
4.18 ml of benzyl chloroformate are added at a temperature of 2° to 5° to a solution of 5.28 ml of triethylamine and 6.3 g of (2S,3S)-1-amino-3-BOC-amino-4-cyclohexyl-2-butanol in 120 ml of dichloromethane, and the solution obtained is stirred for 30 minutes at room temperature. The solution is then diluted with dichloromethane and washed with 0.25N hydrochloric acid, saturated aqueous sodium bicarbonate solution and water. The organic phase is dried over sodium sulphate and evaporated under vacuum. Chromatography of the residue on silica gel using toluene/ethyl acetate (3:1) as the eluant yields (2S,3S)-3-BOC-amino-1-Cbz-amino-4-cyclohexyl-2-butanol as a slightly yellowish oil.
b) (2S,3S)-3-amino-1-Cbz-amino-4-cyclohexyl-2-butanol
8.06 g of the (2S,3S)-compound obtained in section a) are added whilst cooling to 80 ml of the mixture of acetic acid/conc. hydrochloric acid (9:1), and the solution obtained is stirred at room temperature for 1 hour and then evaporated to dryness. The hydrochloride of the above title compound is thus obtained as a colourless foam.
c) (2S,3S)-3-(BOC-phenylalaninyl-norleucinyl)amino-1-Cbz-amino-4-cyclohexyl-2-butanol
4.06 ml of diphenylphosphoryl-azide and 4.94 ml of triethylamine are gradually added to an ice-cooled solution of 6.68 g of BOC-Phe-Nle-OH and 6.3 g of crude hydrochloride of the (2S,3S)-compound described in section b) in dimethylformamide, and the clear solution obtained is stirred over night at room temperature, then concentrated under vacuum, taken up in dichloromethane, and the dichloromethane solution is washed with 0.25N hydrochloric acid, saturated aqueous sodium bicarbonate solution and water, and dried over anhydrous sodium sulphate. After evaporation under vacuum, the residue is chromatographed on silica gel [dichloromethane/ethanol (49:1) as the eluant] and the product obtained is crystallised from dichloromethane/hexane. The title compound thus obtained melts at 167°-168° (decomp.).
d) (2S,3S)-1-amino-3-(BOC-phenylalaninyl-norleucinyl)-amino-4-cyclohexyl-2-butanol
7.0 g of the (2S,3S)-compound obtained in section c) and 0.7 g of palladium on active charcoal (10%) in 140 ml of methanol are hydrogenated for 11/2 hours at room temperature in a hydrogen atmosphere at atmospheric pressure, and the mixture is subsequently diluted with dichloromethane and filtered through Celite. After evaporation of the filtrate under vacuum and crystallisation of the residue from methanol/ether, the title compound is obtained as colourless crystals having a m.p. of 140°-141°, [α]D 20 =-38.5° (c=1 in methanol).
500 mg of H-Tmsal-His-Cha(OH)Bly-NHBu are reacted analogously to example 1 in dimethylformamide with 206 mg of 3EG-OH, 110 mg of hydroxybenzotriazole and 144 mg of diisopropylcarbodiimide. The crude product is chromatographed with methanol/methylene chloride (2-10%). [α]D 20 =-27.6° (c=0.1 in CH2 Cl2).
700 mg of H-Phe-Nle-Cha(OH)Bly-NHBu and 700 mg of Clof-4eg-p-nitrophenol are dissolved in a small amount of dimethylformamide and after addition of 50 mg of 4-dimethylaminopyridine the mixture is heated to 40° during 15 hours. After partitioning between ethylacetate and a saturated aquous sodium bicarbonate solution the organic phase is separated, dried and evaporated. The crude product is recrystallised from methylene chloride/methanol/ether. [α]D 20 =-16.7° (c=0.8 in CH2 Cl2).
500 mg of H-Tmsal-His-Cha(OH)Bly-NHBu are reacted analogously to example 1 in a small amount of dimethylformamide with 338 mg of 7EG-OH, 110 mg of hydroxybenzotriazole and 131 ml of diisopropylcarbodiimide. The crude product is chromatographed with methanol/methylene chloride (5:95). The title compound has a [α]D 20 =21.0° (c=0.1 in CH2 Cl2).
700 mg of H-Tmsal-His-Chatin-Leu-α-Pic are reacted analogously to example 22 with 350 mg of Me3eg-p-nitrophenol and 500 mg of 4-dimethylaminopyridine. The crude product is chromatographed with methanol/methylene chloride (1-10%). The title compound has a [α]D 20 =-26.5° (c=0.2 in CH2 Cl2).
According to example 24 the title compound acylated on the histidine moiety is obtained as by product. [α]D 20 =-4.7° (c=0.8 in CH2 Cl2).
830 mg of H-Phe-Nle-CHa(OH)CH2 PO(OMe)2 in 15 ml of dimethylformamide/tetrahydrofurane (1:1) are reacted with 310 mg of hydroxybenzotriazole, 330 mg of 3EG-OH and 300 mg of N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide-hydrochloride (EDCI). After 24 hours the mixture is evaporated and to the residue an aqueous sodium bicarbonate solution is added at 0°. The precipitate is dissolved in ethylacetate and the organic phase first washed with 2N hydrochloric acid and then with a saturated aqueous sodiumchloride solution. After drying over sodiumsulphate and evaporation the crude product is purified on silicagel with methylene chloride/ethanol (19:1). The title compound has a [α]D 25 =-38.7° (c=0.5 in CH2 Cl2).
553 mg of H-Tmsal-Nle-F2 -Chatin-NHiBu are reacted analogously to example 22 with 381 mg of Niacin-2eg-p-nitrophenol. The title compound has a [α]D 20 =-24.5° (c=0.1 in CH2 Cl2).
600 mg of the title compound of example 27 are oxidised analogously to example 7 with 3.1 g of Collin's reagens. [α]D 20 =-32.6° (c=0.8 in CH2 Cl2).
100 mg of H-Phe-Nle-Cha(OH)Bly-NHBu are reacted in dimethylformamide with 50 mg of 3,6,9-trioxadecyljodide and 50 mg of ethyldiisopropylamine. After 100 hours the reaction product is isolated and chromatographed with methanol/methylene chloride (1-10%). [α]D 20 =-46.5° (c=0.15 in CH2 Cl2).
400 mg of H-Tmsal-Nle-Chatin-Leu-α-Pic are reacted analogously to example 1 with 260 mg of 7EG-OH, 80 mg of hydroxybenzotriazole and 130 mg of N,N'-dicyclohexylcarbodiimide. The crude product is chromatographed with 5% methanol in methylene chloride. [α]D 20 =-3.9° (c=0.8 in CH2 Cl2).
500 mg of H-Tmsal-Nle-Chatin-leu-α-Pic are reacted analogously to example 22 in dimethylformamide with 300 mg of Niacin-2eg-p-nitrophenol. The crude product is cristallised from methylene chloride/ether. [α]D 20 =-27.2° [c=0.25 in CH2 Cl2 /MeOH (1:1)].
32 mg of the title compound of example 28 are dissolved in methanol and hydrolised with 4 mg sodiumhydroxide. The reaction mixture is partitioned between aqueous sodium bicarbonate and methylene chloride, the organic phase dried and evaporated [α]D 20 =-27.1° (c=0.6 in CH2 Cl2).
325 mg of H-Phe-Nle-Cha(OH)Bualy-NHBu in 6 ml of dimethylformamide/tetrahydrofurane (1:1) are reacted analogously to example 26 with 193 mg of hydroxybenzotriazole, 118 mg of 3EG-OH and 210 mg of N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide.HCl. The crude product is purified on silicagel with methylene chloride/ethanol (19:1). [α]D 25 =-18.7° (c=0.475 in CH2 Cl2).
440 mg of H-Tmsal-Nle-F2 -Chatin-NHiBu are reacted analogously to example 22 with 370 mg of H-Tmpac-2eg-p-nitrophenol. The crude product is purified by chromatography on silicagel. [α]D 20 =-19.3° (c=0.1 in CH2 Cl2).
20 mg of title compound of example 34 are oxidised analogously to example 7 with 100 mg of Collin's reagens. [α]D 20 =-21.0° (c=0.2 in CH2 Cl2).
352 mg of H-Ada-Nle-Cha(OH)CH2 CHCl-NHBu.HCl in 3.5 ml of dimethylformamide/tetrahydrofurane (1:1) are reacted analogously to example 26 with 120 mg hydroxybenzotriazole, 0.0815 ml of N-ethylmorpholine, 174 mg of 3EG-OH and 105 mg of N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide.HCl. The crude product is purified on silicagel (Lichroprep 25-40) with methylene chloride/ethanol (49:1). [α]D 20 =-14.9° (c=0.53 in CH2 Cl2).
502 mg of H-Tmsal-Nle-Cha(OH)Bly-NHBu in 2.3 ml of tetrahydrofurane/dimethylformamide (1:1) are reacted analogously to example 26 with 208 mg of hydroxybenzotriazole, 151 mg of 3EG-OH and 143 mg of N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide.HCl. The crude product is cristallised from methylene chloride/hexane. [α]D 20 =-31.4° (c=0.50 in CH2 Cl2).
338 mg of H-Tmsal-Nle-Cha(OH)CH2 CHCl-NHBu.HCl in 3.7 ml of dimethylformamide/tetrahydrofurane (1:1) are reacted analogously to example 26 with 127 mg of hydroxybenzotriazole, 0.0862 ml of N-ethylmorpholine, 184 mg of 3EG-OH and 111 mg of N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide.HCl. The crude product is chromatographed on silica gel (Lichroprep RP-18, 40-63) with methanol/water (8:2). [α]D 25 =-22.8° (c=0.6 in CH2 Cl2).
490 mg of H-Ada-Nle-Cha(OH)CH2 CHF-NHBu.HCl in 5.0 ml dimethylformamide/tetrahydrofurane (1:1) are reacted analogously to example 26 with 172 mg of hydroxybenzotriazole, 0.0986 ml of N-methylmorpholine, 248 mg of 3EG-OH and 150 mg of N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide.HCl. The crude product is purified on silicagel (Lichroprep RP-18, 40-63) with acetonitrile/water (8:2). [α]D 25 =-21.8° (c=0.33 in CH2 Cl2).
614 mg of H-Phe-Nle-Cha(OH)CH2 CHCl-NHBu.HCl in 6.5 ml dimethylformamide/tetrahydrofurane (1:1) are reacted analogously to example 26 with 224 mg of hydroxybenzotriazole, 0.127 ml of N-Methylmorpholine, 324 mg of 3EG-OH and 196 mg of N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide.HCl. The crude product is cristallised from ethanol/ether/hexane. [α]D 25 =-19.8° (c=0.555 in MeOH).
280 mg of H-Ada-Nle-Cha(OH)Fala-NHBu in 2.8 ml of dimethylformamide/tetrahydrofurane (1:1) are reacted analogously to example 26 with 96 mg of hydroxybenzotriazole, 0.055 ml of N-methylmorpholine, 139 mg of 3EG-OH and 84 mg of N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide.HCl. The crude product is purified on silicagel with methylene chloride/ethanol (49:1). [α]D 25 =-35.4° (c=0.48 in CH2 Cl2).
340 mg of H-Cha(OH)Bly-NHBu, 220 mg of 3EG-OH, 310 mg of N,N'-dicyclohexylcarbodiimide and 310 mg of 1-hydroxybenzotriazole are reacted in 10 ml of dimethylformamide analogously to example 1. [α]D 20 =-22.7° (c=1 in methylene chloride).
387 mg of H-Ada-Nle-Cha(OH)CH2 CH(N3)-NHBu in 3.9 ml of dimethylformamide/tetrahydrofurane (1:1) are reacted analogously to example 26 with 135 mg of hydroxybenzotriazole, 196 mg of 3EG-OH and 118 mg of N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide.HCl. The crude product is chromatographed on neutral aluminiumoxide (akt. III) with methylene chloride/ethanol (19:1). The title product is lyophilisated with benzene. [α]D 25 =-16.4° (c=0.555 in CH2 Cl2).
416 mg of H-Phe-Nle-Cha(OH)CH2 CH(S-iPr)-NHBu in 4.5 ml of dimethylformamide/tetrahydrofurane (1:1) are reacted analogously to example 26 with 154 mg of hydroxybenzotriazole, 224 mg of 3EG-OH and 135 mg of N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide.HCl. The crude product is purified on neutral aluminiumoxide (akt. III) with methylene chloride/ethanol (49:1-19:1) and then crystallised from methylene chloride/ether/hexane. [α]D 25 =-17.1° (c=0.25 in MeOH).
440 mg of 3EG-OH, 1.15 g of H-His-Cha(OH)Bly-NHBu, 620 mg of 1-hydroxybenzotriazole and 420 mg of N,N'-dicyclohexylcarbodiimide are reacted in 20 ml of dimethylformamide analogously to example 1. M.p. 128°-130°, [α]D 25 =-33.0° (c=1 in methanol).
260 mg of H-Thala-Nle-Chatin-Leu-α-Pic are reacted analogously to example 1 in 3 ml dimethylformamide with 100 mg of hydroxybenzotriazole, 84 mg of 3EG-OH and 78 mg of N,N'-dicyclohexylcarbodiimide. The crude product is chromatographed on silica gel with methylene chloride containing 7% ethanol. [α]D 20 =-16.7° (c=0.37 in ethanol).
The compounds according to the invention exhibit pharmacological activity and are, therefore, useful as pharmaceuticals.
They are inhibitors of renin activity, e.g. on human tetradecapeptide substrate at a concentration of 10-5 M to 10-11 M they inhibit the enzyme activity of pure human renin by 50% according to the method of F. Cumin et al. (Bioch. Biophys. Acta 913, 10 to 19 (1987)) or in a renin binding assay.
In the antibody-trapping method of K. Poulsen and J. Jorgensen (J. Clin. Endocrin. Metab. 39, [1974] 816-825), they inhibit human plasma renin activity at a concentration of 10-5 M to 10-11 M.
The compounds according to the invention are therefore useful for the prophylaxis and treatment of conditions which are characterised by enzymatic malfunction and for which an inhibition of enzymatic activity is indicated.
As renin inhibitors they are suitable e.g. for use in the prophylaxis and treatment of hypertension and cardiac insufficiency ("congestive heart failure").
The compounds which are preferred for the prophylaxis and treatment of hypertension and cardiac insufficiency are the title compounds of examples 2, 3, 8 to 11, 13, 18, 19, 21 and 46, especially of examples 8 to 11, 13, 21 and 46, particularly of examples 13, 21 and 46, most preferred the compound of example 46.
The title compound of example 46 is the most preferred compound for the renin inhibition, it has for example been determined in the antibody trapping test having the lowest inhibiting concentration 0,15 nM/l, the highest inhibiting concentration 15 nM/l, IC50 =1,5 nM/l, it is therefore indicated that the compound of example 46 may be administered to larger mammals such as humans at daily dosage from 1 mg to 10 mg.
The compounds according to the invention exhibit also an antiretroviral activity and are therefore useful for the treatment of diseases caused by retroviruses including HTLV-I and -III. This activity can be demonstrated in the FeLV cat model [Cerny and Essex, CRC press in 1979, pp. 233-256; Cockerell et al., J. Natl. Cancer Inst. 57, 1095-1099 (1976); Cotter et al. J. Am. Vet. med. Assoc. 166, 449-453 (1975); Essex et al. Science 190, 790-792 (1975)]- a disease model for human AIDS.
It has been reported e.g. (25th ICAAC in Minneapolis, Sept. 30th-Oct. 2nd) that with a 30 mg treatment of 3'-azido-3'-deoxy-thymidine over 14 days a reduction of FeLV-titres by a factor of 10 could be shown, but no cure was achieved. On administration of the compounds of the invention, eradication of the virus can be observed. Dosage ranges for the anti-retro-viral activity are those conventionally employed and lie e.g. in the range of 5-20 mg/kg/day.
For above indications, the dosage to be administered depends on the compound respectively used, the type of administration and the desired treatment. In general, satisfactory results are obtained if the compounds are administered in a daily dosage of 0.02 mg/kg to ca. 20 mg/kg animal body weight. For larger mammals, for example humans an indicated daily dosage is from about 1 mg to about 500 mg, conveniently administered e.g. orally in doses of 0.25 mg to ca. 500 mg up to 4 times daily e.g. in divided form.
The compounds according to the invention may be administered in free form, or if acidic or basic groups are present, in pharmacologically acceptable salt form. Such salt forms have the same order of activity as the free forms and can be produced in known manner. The present invention similarly relates to pharmaceutical preparations containing a compound according to the invention in free form or in pharmaceutically acceptable salt form, optionally together with pharmaceutically adjuvants and/or carrier substances. Such pharmaceutical preparations may be formulated for use in enteral, preferably oral administration, e.g. at tablets, or for use in parenteral administration, e.g. as injectable solutions or suspensions. Further a nasal administration of the compounds according to the invention is also possible. An appropriate nasal spray can be prepared in a manner known per se.
Claims (7)
1. Hydrophilic renin inhibitors of formula ##STR22## wherein W is --O--, --NR2 -- or --CH2, whereby R2 signifies hydrogen or a straight-chain or branched (C1-5)alkyl radical,
R1 is pyridinoyl;
R2 is defined as above;
m is a whole number from 1 to 20,
n is a whole number from 0 to 5, and
o is 2 or 3,
A, B and C are the same or different and signify a bond or a group of formula ##STR23## wherein R2 is defined as above, and
R3 signifies a hydrophilic or lipophilic amino acid side chain, or
R2 and R3 together form a --(CH2)o -- chain, wherein o is defined as above,
D signifies either a group of formula ##STR24## wherein R4 has the same significance as R3,
R5 is hydroxyl or an amino group, and
R6 is hydrogen, or
R5 and R6 together form an oxo group,
R7 and R8, independently of one another, signify fluorine or hydrogen;
R9 and R10 are the same or different and respectively signify hydrogen, a straight-chain or branched (C1-5)-alkyl radical, or they respectively signify a group of formula ##STR25## wherein R11 signifies a straight-chain or branched (C1-5)-alkyl radical or a straight-chain or branched (C1-5)-hydroxyalkyl radical;
R12 is a hydroxyl radical, a straight-chain or branched (C1-5)-alkoxy group, an amino group or a (C1-5)-alkylamino group, an aminomethylpyridyl group, a benzyl group or a group of formula ##STR26## wherein R1 and m are defined as above, or R1 denote a protected or unprotected amino acid;
X signifies a bond or denotes ##STR27## wherein R13 and R14, independently of one another, denote hydrogen or fluorine, or respectively possess the definition given above for R3, or
D signifies a group of formula ##STR28## wherein R4, R5, R9, R10 and X possess the definitions given above, and
Z is ##STR29## or D signifies a group of formula ##STR30## wherein R4, R11 and R12 possess the definitions given above, and their salts.
2. A compound of the formula:
R.sub.1 --O--(CH.sub.2 CH.sub.2 O).sub.m --CO--A--B--C--D (I)
wherein
R1 is pyridoyl,
m is an interger of from 2 to 7,
A, B, and C are each independently a bond or a group of the formula ##STR31## where R2 is hydrogen or straight or branched chain (C1-5)alkyl and,
R3 is cyclohexylmethyl, trimethylsilylmethyl, isobutyl, or 2-butenyl, and
D is a group of the formula ##STR32## where R4 is the same as R2,
R5 is hydroxyl and R6 is hydrogen or
R5 and R6 together are oxo,
R7 and R8 are each independently hydrogen or fluorine,
X is a bond,
R9 is hydrogen and
R10 is straight or branched chain (C1-5)alkyl or a group of the formula ##STR33## where R11 is straight or branched chain (C1-5)alkyl and
R12 is aminomethylpyridyl.
3. The compound according to claim 2, which is (3R,4S,7S,10R)-5,8,11-triaza-7-butyl-4-cyclohexylmethyl-2,2-difluoro-3-hydroxy-19-nicotinoyl-10-trimethylsilymethyl-13,16,19-trioxa-6,9,12-trioxo-nonadecanic acid isobutylamide.
4. The compound according to claim 2, which is (4S,7S,10R)-5,8,11-triaza-7-butyl-4-cyclohexylmethyl-2,2-difluoro-19-nicotinoyl-10-trimethylsilymethyl-13,16,19-trioxa-3,6,9,12-tetraoxo-nonadecanic acid isobutylamide.
5. The compound according to claim 2, which is (3S,4S,7S,10R)-5,8,11-triaza-7-butyl-4-cyclohexylmethyl-3-hydroxy-19-nicotinoyl-10-trimethylsilylmethyl-13,16,19-trioxa-6,9,12-trioxo-nonadecanoyl-(L)-leuzine-(2-picolylamide).
6. A method of preventing or treating diseases caused by retroviruses which comprises administering to an animal in need of such treatment a therapeutically effective amount of a compound of claim 1.
7. A pharmaceutical composition useful in treating diseases caused by retroviruses comprising an appropriate amount of a compound of claim 1 in free form or in pharmaceutically acceptable salt form, in association with a pharmaceutical carrier or diluent.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3730895 | 1987-09-15 | ||
DE3730895 | 1987-09-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
US5045537A true US5045537A (en) | 1991-09-03 |
Family
ID=6336013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/244,220 Expired - Fee Related US5045537A (en) | 1987-09-15 | 1988-09-14 | Hydrophilic renin inhibitors, their preparation and use |
Country Status (8)
Country | Link |
---|---|
US (1) | US5045537A (en) |
JP (1) | JPH01151544A (en) |
BE (1) | BE1003071A5 (en) |
CH (1) | CH677672A5 (en) |
DE (1) | DE3830825A1 (en) |
FR (1) | FR2620451B1 (en) |
GB (1) | GB2209752B (en) |
IT (1) | IT1224742B (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5364844A (en) * | 1988-01-26 | 1994-11-15 | Sankyo Company, Limited | Renin-inhibitory oligopeptides, their preparation and use |
US5760019A (en) * | 1996-07-12 | 1998-06-02 | The Research Foundation Of State University Of New York | Silanol enzyme inhibitors |
US5869605A (en) * | 1992-10-30 | 1999-02-09 | Rhone-Poulencchimie | Protected compound comprising a protective group removably attached to a compound to be protected |
US6096762A (en) * | 1998-06-02 | 2000-08-01 | Bristol-Myers Squibb Company | Neurotrophic difluoroamide agents |
US6359113B1 (en) | 1990-12-31 | 2002-03-19 | Rhodia Chimie | Protective group, compound protected by said group and device for grafting the protective group on the compound to protect it |
US7012086B1 (en) | 2000-06-30 | 2006-03-14 | The Foundation For Innovative Therapies, Inc. | Treatment of retrovirus induced derangements with niacin compounds |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5407190A (en) * | 1989-04-18 | 1990-11-16 | Upjohn Company, The | Peptides having novel polar n-terminal groups |
US5098924A (en) * | 1989-09-15 | 1992-03-24 | E. R. Squibb & Sons, Inc. | Diol sulfonamide and sulfinyl renin inhibitors |
DE69126987T2 (en) * | 1990-11-19 | 1998-03-05 | Monsanto Co | RETROVIRAL PROTEASE INHIBITORS |
US5475027A (en) * | 1990-11-19 | 1995-12-12 | G.D. Searle & Co. | Retroviral protease inhibitors |
US5475013A (en) * | 1990-11-19 | 1995-12-12 | Monsanto Company | Retroviral protease inhibitors |
US5614522A (en) * | 1990-11-19 | 1997-03-25 | G.D. Searle & Co. | Retroviral protease inhibitors |
US5583238A (en) * | 1990-11-19 | 1996-12-10 | G. D. Searle & Co. | Method for making intermediates useful in synthesis of retroviral protease inhibitors |
EP0731088B1 (en) * | 1990-11-19 | 2000-10-04 | Monsanto Company | Retroviral protease inhibitors |
US5648511A (en) * | 1990-11-19 | 1997-07-15 | G.D. Searle & Co. | Method for making intermediates useful in the synthesis of retroviral protease inhibitors |
ES2059293T3 (en) * | 1990-11-19 | 1998-12-16 | Monsanto Co | RETROVIRAL PROTEASE INHIBITORS. |
US5482947A (en) | 1990-11-19 | 1996-01-09 | Talley; John J. | Retroviral protease inhibitors |
US5510378A (en) * | 1990-11-19 | 1996-04-23 | G.D. Searle & Co. | Retroviral protease inhibitors |
ATE199545T1 (en) * | 1992-05-21 | 2001-03-15 | Monsanto Co | INHIBITORS OF RETROVIRAL PROTEASES |
KR100336699B1 (en) | 1992-08-25 | 2002-05-13 | 윌리암스 로저 에이 | Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US6743929B1 (en) | 1992-08-25 | 2004-06-01 | G. D. Searle & Co. | Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US7141609B2 (en) | 1992-08-25 | 2006-11-28 | G.D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US5760076A (en) * | 1992-08-25 | 1998-06-02 | G.D Searle & Co. | Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US5968942A (en) | 1992-08-25 | 1999-10-19 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
KR100296461B1 (en) * | 1992-08-25 | 2001-11-14 | 죤 에이치. 뷰센 | N- (alkanoylamino-2-hydroxypropyl) -sulfonamide useful as a retroviral protease inhibitor |
US5521219A (en) * | 1992-08-25 | 1996-05-28 | G. D. Searle & Co. | Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US6022994A (en) | 1992-08-25 | 2000-02-08 | G. D. Searle &. Co. | Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US6046190A (en) * | 1992-08-25 | 2000-04-04 | G.D. Searle & Co. | Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors |
US5830897A (en) * | 1992-08-27 | 1998-11-03 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
DE69331421T2 (en) | 1992-10-30 | 2002-08-01 | G.D. SEARLE & CO., CHICAGO | N-substituted hydroxyethylaminosulfamic acid derivatives can be used as inhibitors of retroviral proteases |
US5578606A (en) | 1992-10-30 | 1996-11-26 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors |
PT885881E (en) * | 1992-10-30 | 2003-07-31 | Searle & Co | ACIDS SULFONYLCANOYLAMINO HYDROXYETHYLAMINE USEFUL SULFAMICOS AS RETROVIRAL PROTEASE INHIBITORS |
AU5589294A (en) * | 1992-10-30 | 1994-05-24 | G.D. Searle & Co. | Succinoylamino hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors |
US5756498A (en) * | 1992-10-30 | 1998-05-26 | G.D. Searle & Co. | Sulfonylalkanoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors |
US6337398B1 (en) | 1992-10-30 | 2002-01-08 | G.D. Searle & Co. | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors |
US5514801A (en) | 1992-12-29 | 1996-05-07 | Monsanto Company | Cyclic sulfone containing retroviral protease inhibitors |
US5830888A (en) * | 1993-04-16 | 1998-11-03 | Monsanto Company | Macrocyclic retroviral protease inhibitors |
US5750648A (en) * | 1993-08-20 | 1998-05-12 | G.D. Searle & Co. | Retroviral protease inhibitors and combinations thereof |
US5602119A (en) * | 1993-10-29 | 1997-02-11 | Vazquez; Michael L. | Succinoylamino hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors |
US6133444A (en) * | 1993-12-22 | 2000-10-17 | Perseptive Biosystems, Inc. | Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions |
UA49803C2 (en) * | 1994-06-03 | 2002-10-15 | Дж.Д. Сьорль Енд Ко | Method for treatment of retrovirus infections |
CA2210889C (en) * | 1995-01-20 | 2007-08-28 | G.D. Searle & Co. | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors |
US5831117A (en) | 1995-01-20 | 1998-11-03 | G. D. Searle & Co. | Method of preparing retroviral protease inhibitor intermediates |
US6140505A (en) | 1995-03-10 | 2000-10-31 | G. D. Searle & Co. | Synthesis of benzo fused heterocyclic sulfonyl chlorides |
US5756533A (en) * | 1995-03-10 | 1998-05-26 | G.D. Searle & Co. | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
US6667307B2 (en) | 1997-12-19 | 2003-12-23 | G.D. Searle & Co. | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors |
US5985870A (en) * | 1995-03-10 | 1999-11-16 | G.D. Searle & Co. | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors |
US6407134B1 (en) | 1995-03-10 | 2002-06-18 | G. D. Searle & Co. | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
US7339078B2 (en) | 1995-03-10 | 2008-03-04 | G.D. Searle Llc | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
US5705500A (en) * | 1995-03-10 | 1998-01-06 | G.D. Searle & Co. | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors |
EP1188766A1 (en) | 1995-03-10 | 2002-03-20 | G.D. Searle & Co. | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
DE69625183T2 (en) * | 1995-03-10 | 2003-10-09 | G.D. Searle & Co., Chicago | HETEROCYCLOCARBONYL-AMINO ACID-HYDROXYETHYLAMINO-SULFONAMIDE INHIBITORS OF RETROVIRAL PROTEASES |
US6169085B1 (en) | 1995-03-10 | 2001-01-02 | G. D. Searle & Company | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors |
US5776971A (en) * | 1995-03-10 | 1998-07-07 | G.D. Searle & Co. | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
US6150556A (en) * | 1995-03-10 | 2000-11-21 | G. D. Dearle & Co. | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
US6861539B1 (en) | 1995-03-10 | 2005-03-01 | G. D. Searle & Co. | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
AU7722296A (en) * | 1995-11-15 | 1997-06-05 | G.D. Searle & Co. | Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors |
EP1095022A1 (en) | 1998-07-08 | 2001-05-02 | G.D. Searle & Co. | Retroviral protease inhibitors |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3377497D1 (en) * | 1982-09-15 | 1988-09-01 | Haessle Ab | Enzyme inhibitors |
-
1988
- 1988-09-10 DE DE3830825A patent/DE3830825A1/en not_active Withdrawn
- 1988-09-12 FR FR8811952A patent/FR2620451B1/en not_active Expired - Fee Related
- 1988-09-12 BE BE8801045A patent/BE1003071A5/en not_active IP Right Cessation
- 1988-09-12 CH CH3397/88A patent/CH677672A5/de not_active IP Right Cessation
- 1988-09-13 GB GB8821442A patent/GB2209752B/en not_active Expired - Lifetime
- 1988-09-14 US US07/244,220 patent/US5045537A/en not_active Expired - Fee Related
- 1988-09-14 JP JP63231395A patent/JPH01151544A/en active Pending
- 1988-09-14 IT IT8848347A patent/IT1224742B/en active
Non-Patent Citations (2)
Title |
---|
Cumin et al., "Biochem., Biophys. Acta", vol. 913, pp. 10-19, (1987). |
Cumin et al., Biochem., Biophys. Acta , vol. 913, pp. 10 19, (1987). * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5364844A (en) * | 1988-01-26 | 1994-11-15 | Sankyo Company, Limited | Renin-inhibitory oligopeptides, their preparation and use |
US6359113B1 (en) | 1990-12-31 | 2002-03-19 | Rhodia Chimie | Protective group, compound protected by said group and device for grafting the protective group on the compound to protect it |
US5869605A (en) * | 1992-10-30 | 1999-02-09 | Rhone-Poulencchimie | Protected compound comprising a protective group removably attached to a compound to be protected |
US5760019A (en) * | 1996-07-12 | 1998-06-02 | The Research Foundation Of State University Of New York | Silanol enzyme inhibitors |
US20030096793A1 (en) * | 1996-07-12 | 2003-05-22 | Research Foundation Of State University Of New York | Silanol enzyme inhibitors |
US6960678B2 (en) | 1996-07-12 | 2005-11-01 | The Research Foundation Of State University Of New York | Silanol enzyme inhibitors |
US6096762A (en) * | 1998-06-02 | 2000-08-01 | Bristol-Myers Squibb Company | Neurotrophic difluoroamide agents |
US7012086B1 (en) | 2000-06-30 | 2006-03-14 | The Foundation For Innovative Therapies, Inc. | Treatment of retrovirus induced derangements with niacin compounds |
Also Published As
Publication number | Publication date |
---|---|
FR2620451B1 (en) | 1993-12-24 |
GB8821442D0 (en) | 1988-10-12 |
GB2209752B (en) | 1991-06-05 |
JPH01151544A (en) | 1989-06-14 |
IT1224742B (en) | 1990-10-18 |
IT8848347A0 (en) | 1988-09-17 |
FR2620451A1 (en) | 1989-03-17 |
DE3830825A1 (en) | 1989-03-23 |
GB2209752A (en) | 1989-05-24 |
CH677672A5 (en) | 1991-06-14 |
BE1003071A5 (en) | 1991-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5045537A (en) | Hydrophilic renin inhibitors, their preparation and use | |
US4691007A (en) | Proline derivatives | |
EP0184550B1 (en) | 5-amino-4-hydroxy valeryl amide derivatives | |
AU599367B2 (en) | Novel amino acid derivatives | |
JPS61236770A (en) | Novel amino acid derivative | |
AU2885292A (en) | Peptides inhibiting il-1 beta release | |
EP0216539A2 (en) | Novel amino acid derivatives | |
US4656269A (en) | Histidine derivatives | |
US4382889A (en) | Epoxysuccinic acid derivatives | |
EP0190891A2 (en) | Novel amino acid derivatives | |
EP0206807A2 (en) | Novel amino acid derivatives | |
EP0252727A1 (en) | Novel amino acid derivatives | |
HU206194B (en) | Process for producing cyclomethylene-1,2-dicarboxylic acid derivatives and pharmaceutical compositions comprising same | |
US4490386A (en) | Phosphate salts of 1-[2-[(1-alkoxycarbonyl-3-aralkyl)-amino]-1-oxoalkyl]octahydro-1H-indole-2-carboxylic acids, preparation of, and medical compositions thereof | |
GB2212158A (en) | Trialkylsilymethyl-substituted peptides; renin inhibitors | |
US5922697A (en) | Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins | |
Bundy et al. | Potent renin inhibitory peptides containing hydrophilic end groups | |
US5110798A (en) | Purine derivatives having pharmacological action | |
US5883132A (en) | 15-deoxyspergualin analogs, their use in therapeutics and their method of preparation | |
EP0163286A2 (en) | Acylated sugars, method for their preparation and their use | |
US5091510A (en) | Retro-inverso analogues of thymopentin, and their use in the preparation of pharmaceutical compositions | |
WO1989010917A2 (en) | Renin inhibitors, process for producing them and use thereof | |
Zorc et al. | Reactions with N-(1-benzotriazolylcarbonyl)-amino acids. IV. The use of N-(1-benzotriazolylcarbonyl)-amino acid derivates in peptide synthesis | |
EP0050856B1 (en) | New peptide, process for its preparation and pharmaceutical composition containing it | |
NO860625L (en) | ACYLATED HEXOS DERIVATIVES AND PROCEDURES FOR PREPARING THEREOF. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SANDOZ LTD., A/K/A SANDOZ AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:WEIDMANN, BEAT;REEL/FRAME:005736/0908 Effective date: 19880906 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 19950906 |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |